Actualités et vidéos - APTOSE BIOSCIENCES INC. - Page 2

Vous consultez actuellement toutes les actualités boursières de l'instrument financier APTOSE BIOSCIENCES INC. sur tous les marchés dans toutes les langues.

> Actualités GlobeNewsWire a publié une nouvelle actualité.

Aptose Biosciences Reports Financial Results for the Third Quarter Ended September 30, 2016 • • GlobeNewsWire • Actions

SAN DIEGO and TORONTO, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced unaudited financial results for the three months ended September 30, 2016 and reported on corporate developments. Unless specified otherwise, all amounts are in Canadian dollars. Net loss for the three months ended September 30, 2016 was $4.0 million...

Merci Graphique

> Actualités GlobeNewsWire a publié une nouvelle actualité.

Aptose To Release Third Quarter Ended September 30, 2016 Financial Results and Hold Conference Call on November 15, 2016 • • GlobeNewsWire • Actions

SAN DIEGO and TORONTO, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2016, on Monday, November 14, 2016 after the close of the market. The company intends to host a conference call the following morning on Tuesday, November 15, 2016 at 8:30 a.m. ET to...

Merci Graphique

> Actualités GlobeNewsWire a publié une nouvelle actualité.

Aptose to Present New APTO-253 Data at the 2016 ASH Annual Meeting • • GlobeNewsWire • Actions

SAN DIEGO and TORONTO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that new preclinical data for its lead investigational anticancer therapeutic APTO-253 will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 3-6, 2016, in San Diego, CA. Poster...

Merci Graphique

> Actualités GlobeNewsWire a publié une nouvelle actualité.

Aptose Provides Update on FDA Clinical Hold of APTO-253 • • GlobeNewsWire • Actions

SAN DIEGO and TORONTO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that it received a response from the U.S. Food and Drug Administration (FDA) regarding the clinical hold of Aptose’s Phase 1b clinical trial of APTO-253 in patients with hematologic cancers requesting additional information and informing Aptose...

Merci Graphique